BlackBarn Capital Partners LP Has $23.14 Million Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

BlackBarn Capital Partners LP boosted its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 107.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,050,000 shares of the company's stock after purchasing an additional 543,029 shares during the quarter. Teva Pharmaceutical Industries makes up 1.3% of BlackBarn Capital Partners LP's holdings, making the stock its 4th largest position. BlackBarn Capital Partners LP owned about 0.09% of Teva Pharmaceutical Industries worth $23,142,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of TEVA. Diversify Advisory Services LLC grew its holdings in shares of Teva Pharmaceutical Industries by 2.5% in the fourth quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company's stock valued at $426,000 after purchasing an additional 496 shares during the period. Sanctuary Advisors LLC grew its stake in Teva Pharmaceutical Industries by 1.9% during the 3rd quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company's stock worth $601,000 after buying an additional 664 shares during the last quarter. Thrivent Financial for Lutherans raised its stake in Teva Pharmaceutical Industries by 0.3% during the 4th quarter. Thrivent Financial for Lutherans now owns 225,210 shares of the company's stock valued at $4,964,000 after acquiring an additional 699 shares during the last quarter. Townsquare Capital LLC boosted its holdings in Teva Pharmaceutical Industries by 2.1% in the 4th quarter. Townsquare Capital LLC now owns 40,162 shares of the company's stock valued at $885,000 after purchasing an additional 812 shares in the last quarter. Finally, Metis Global Partners LLC lifted its position in shares of Teva Pharmaceutical Industries by 6.7% during the 4th quarter. Metis Global Partners LLC now owns 13,697 shares of the company's stock valued at $302,000 after acquiring an additional 860 shares during the period. 54.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms recently commented on TEVA. Piper Sandler increased their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a research note on Friday, January 17th. Bank of America dropped their target price on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a research report on Thursday, March 6th. Barclays dropped their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research report on Thursday, January 30th. StockNews.com raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Wednesday. Finally, UBS Group lowered their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research note on Thursday, January 30th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries presently has a consensus rating of "Moderate Buy" and a consensus price target of $23.43.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock opened at $14.71 on Friday. The stock's fifty day simple moving average is $15.26 and its 200-day simple moving average is $17.58. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. The company has a market capitalization of $16.68 billion, a price-to-earnings ratio of -10.14, a P/E/G ratio of 1.44 and a beta of 0.72. Teva Pharmaceutical Industries Limited has a 1-year low of $12.47 and a 1-year high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. On average, sell-side analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.